1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,150 | 5,200 | 26.06. | |
| 4,820 | 5,850 | 26.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Addex Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript | 2 | Benzinga.com | ||
| Do | Addex Therapeutics GAAP EPS of -CHF0.01 | 2 | Seeking Alpha | ||
| Do | Addex Therapeutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| ADDEX THERAPEUTICS SA ADR Aktie jetzt für 0€ handeln | |||||
| Do | Addex fällt im ersten Quartal tiefer ins Minus | 278 | Moneycab | Genf - Das Biotechunternehmen Addex hat im ersten Quartal des Geschäftsjahres 2026 einen etwas grösseren Verlust geschrieben. Die liquiden Mittel beliefen sich auf 0,9 Millionen Franken, nachdem es... ► Artikel lesen | |
| Do | Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | 271 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, June 25, 2026
-
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| Mo | Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026 | 301 | GlobeNewswire (Europe) | Geneva, Switzerland, June 22, 2026
-
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric... ► Artikel lesen | |
| 05.06. | Addex Therapeutics Ltd. - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 05.06. | Addex Therapeutics: Addex Convenes Annual General Meeting 2026 | 357 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, June 5, 2026
-
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 15.05. | Addex Therapeutics Ltd. - 20-F, Annual and transition report of foreign private issuers | 20 | SEC Filings | ||
| 30.04. | Addex Therapeutics reports FY results | 16 | Seeking Alpha | ||
| 30.04. | Earnings Call Transkript: Addex Therapeutics H2 2026 offenbart strategische Neuausrichtung | 13 | Investing.com Deutsch | ||
| 30.04. | Addex Therapeutics Q4 2025 Earnings Call Transcript | 12 | Benzinga.com | ||
| 30.04. | Addex Therapeutics: Addex Reports Full Year 2025 Financial Results and Provides Corporate Update | 558 | GlobeNewswire (Europe) | GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in multiple disease modelsContinued to reposition dipraglurant mGlu5 NAM for brain injury... ► Artikel lesen | |
| 29.04. | Addex Therapeutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 29.04. | Addex Therapeutics: Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model | 410 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art.?53 LR
Geneva, Switzerland, April 29, 2026
-
Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen | |
| 23.04. | Addex Therapeutics: Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026 | 468 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art.?53 LR
Geneva, Switzerland, April 23, 2026
-
Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen | |
| 21.04. | Addex Therapeutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 21.04. | Addex Therapeutics: Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model | 440 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art.?53 LR
Geneva, Switzerland, April 21, 2026
-
Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen | |
| 03.02. | Addex Therapeutics Ltd. - 6-K, Report of foreign issuer | 19 | SEC Filings | ||
| 03.02. | Addex Therapeutics: Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment | 536 | GlobeNewswire (Europe) | Data published in Molecular Psychiatry
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, February 3, 2026
-
Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage... ► Artikel lesen |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 2,456 | -1,68 % | Aurora Cannabis Inc.: Aurora Cannabis Announces Full Year and Fiscal 2026 Fourth Quarter Results with Record Annual Revenue and Adjusted EBITDA | NASDAQ | TSX: ACB
Achieves Record Annual Global Medical Cannabis Net Revenue1 of $288.6 million, representing 18% YoY growth
Delivers Record Annual Adjusted EBITDA1 of $53.8 million... ► Artikel lesen | |
| BAUSCH HEALTH | 4,288 | +2,24 % | Bausch Health Companies Inc.: Bausch Health Announces 2026 Annual Meeting of Shareholder Results | LAVAL, QC, May 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 23,300 | -0,85 % | Assembly Biosciences: Der wichtigste HSV-Moment der Biotech-Geschichte steht bevor | Während sich die Biotech-Welt seit Jahren auf Themen wie Adipositas, neuartige Krebstherapien und künstliche Intelligenz fokussiert, könnte sich im Hintergrund eine der größten unentdeckten Chancen... ► Artikel lesen | |
| BIONANO GENOMICS | 1,140 | 0,00 % | Bionano Genomics: Bionano Announces Hiring of Chief Scientific Officer | SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a leader in genome analysis solutions, today announced the appointment of Alex Hastie, Ph.D., as its Chief Scientific... ► Artikel lesen | |
| AMARIN | 14,100 | +0,71 % | U.S. Supreme Court Ends Amarin Patent Fight, Hikma Prevails | LONDON (dpa-AFX) - The United States Supreme Court has ruled in favor of Hikma Pharmaceuticals PLC (HIK.L
HKMPY) and its wholly owned subsidiary Hikma Pharmaceuticals USA Inc., effectively... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 5,150 | -2,83 % | Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA | CRL Cites Deficiencies at Third-Party Manufacturing Facility No Efficacy or Clinical Safety Deficiencies Identified SEATTLE and VANCOUVER, British Columbia, June 22, 2026 (GLOBE NEWSWIRE) -- Achieve... ► Artikel lesen | |
| ALTIMMUNE | 2,430 | -2,41 % | Leerink initiates Altimmune stock coverage citing liver drug data | ||
| BRIDGEBIO PHARMA | 63,19 | +2,27 % | BridgeBio Pharma, Inc. - 8-K, Current Report | ||
| AURINIA PHARMACEUTICALS | 14,835 | -1,88 % | Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last? | ||
| AKANDA | 11,950 | 0,00 % | Akanda Corp: Akanda Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement | Toronto, Ontario--(Newsfile Corp. - June 18, 2026) - Akanda Corp. (NASDAQ: AKAN) (the "Company" or "Akanda"), today announced that it received a notification letter from the Listing Qualifications... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 2,790 | -4,45 % | Biodexa Pharmaceuticals PLC: Biodexa issues letter to Shareholders | May 14, 2026 Biodexa issues letter to Shareholders Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or... ► Artikel lesen | |
| ARTIVION | 20,600 | -0,96 % | Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS Aortic Arch System | Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that Artivion, Inc. (NYSE: AORT) has closed the transaction to acquire the company. This strategic milestone... ► Artikel lesen | |
| ATYR PHARMA | 0,480 | -0,83 % | aTyr Pharma, Inc.: aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update | Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans to submit an IND in June 2026 for a Phase 3 study of efzofitimod in patients... ► Artikel lesen | |
| AVALO THERAPEUTICS | 16,040 | +0,50 % | Avalo Therapeutics to Join the Russell 2000 and Russell 3000 Indexes | WAYNE, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1ß pathway... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 4,358 | 0,00 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Ra Bispecific Antibody, and Announces ... | - Positive Full Results from Phase 1a Trial of Anti-TSLP/IL-4Ra Bispecific Antibody ATI-052 Exceed Aclaris' Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for... ► Artikel lesen |
Das Unternehmen ADDEX THERAPEUTICS SA ADR kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 4,900 Euro und damit -3,92 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADDEX THERAPEUTICS SA ADR finden Sie auf Wallstreet Online.